| Government to Pursue Various Support Measures to Secure National Industrial Competitiveness, Aiming to Nurture 10,000 SaaS Companies by 2026
| Focus on ICT Companies with New Technologies... SaaS Companies Driving Industrial Growth with Advanced Technologies
| Maximizing Work Efficiency Across Sectors with SaaS, from Medical Data Platforms to AICC and Security
With the government's core nurturing project to secure national industrial competitiveness highlighting 'Software as a Service (SaaS)', the goal of fostering 10,000 SaaS companies by 2026 has been announced. Particularly, attention is focused on ICT companies based on new technologies such as AI, big data, and cloud, centered around building a massive AI ecosystem.
SaaS platforms are gaining attention for their notable advantages. SaaS allows the use of services in a cloud environment without the need for separate system construction or specialized personnel, providing excellent strengths in terms of time and cost. Additionally, it aids in enhancing corporate competitiveness by quickly adopting services tailored to rapidly changing digital environments.
As expectations for innovative SaaS companies with advanced technological capabilities grow, various sector-specific SaaS companies are intensifying their service upgrades, driving industrial growth.
■ JNPMEDI Leading Clinical Trial Digitization with SaaS-Based Clinical Solution 'Maven Clinical Cloud'
Medical data platform company JNPMEDI operates the SaaS-based clinical operation and data management solution 'Maven Clinical Cloud', enhancing the competitiveness of the domestic pharmaceutical and biotech industry.
JNPMEDI has been leading the market with advanced SaaS-based clinical solutions in the clinical market, which have been fully transitioning to digital post-pandemic. The Maven Clinical Cloud supports decentralized clinical trials (DCT) with the 'Maven DCT Suite', clinical trial document management with 'Maven Docs', and clinical data collection using mobile devices with 'eCOA (Clinical Outcome Assessment)'. It also includes various digital technology-based solutions such as subject recruitment, consent, and screening.
The pay-as-you-go policy applied to the Maven Clinical Cloud allows sponsors such as pharmaceutical companies and CROs to selectively combine services based on their needs, making it cost-effective. This not only reduces the massive costs involved in traditional clinical processes but also helps sponsors secure funds, leading to positive profit generation effects. Particularly, JNPMEDI's solutions built on a SaaS basis secure server costs and time while providing various benefits.
Built on robust blockchain technology, the Maven Clinical Cloud offers benefits to sponsors with its data integrity, high accuracy, and verified reliability, solidifying its position as a new growth engine leading the future of clinical research.
| Government to Pursue Various Support Measures to Secure National Industrial Competitiveness, Aiming to Nurture 10,000 SaaS Companies by 2026
| Focus on ICT Companies with New Technologies... SaaS Companies Driving Industrial Growth with Advanced Technologies
| Maximizing Work Efficiency Across Sectors with SaaS, from Medical Data Platforms to AICC and Security
With the government's core nurturing project to secure national industrial competitiveness highlighting 'Software as a Service (SaaS)', the goal of fostering 10,000 SaaS companies by 2026 has been announced. Particularly, attention is focused on ICT companies based on new technologies such as AI, big data, and cloud, centered around building a massive AI ecosystem.
SaaS platforms are gaining attention for their notable advantages. SaaS allows the use of services in a cloud environment without the need for separate system construction or specialized personnel, providing excellent strengths in terms of time and cost. Additionally, it aids in enhancing corporate competitiveness by quickly adopting services tailored to rapidly changing digital environments.
As expectations for innovative SaaS companies with advanced technological capabilities grow, various sector-specific SaaS companies are intensifying their service upgrades, driving industrial growth.
■ JNPMEDI Leading Clinical Trial Digitization with SaaS-Based Clinical Solution 'Maven Clinical Cloud'
Medical data platform company JNPMEDI operates the SaaS-based clinical operation and data management solution 'Maven Clinical Cloud', enhancing the competitiveness of the domestic pharmaceutical and biotech industry.
JNPMEDI has been leading the market with advanced SaaS-based clinical solutions in the clinical market, which have been fully transitioning to digital post-pandemic. The Maven Clinical Cloud supports decentralized clinical trials (DCT) with the 'Maven DCT Suite', clinical trial document management with 'Maven Docs', and clinical data collection using mobile devices with 'eCOA (Clinical Outcome Assessment)'. It also includes various digital technology-based solutions such as subject recruitment, consent, and screening.
The pay-as-you-go policy applied to the Maven Clinical Cloud allows sponsors such as pharmaceutical companies and CROs to selectively combine services based on their needs, making it cost-effective. This not only reduces the massive costs involved in traditional clinical processes but also helps sponsors secure funds, leading to positive profit generation effects. Particularly, JNPMEDI's solutions built on a SaaS basis secure server costs and time while providing various benefits.
Built on robust blockchain technology, the Maven Clinical Cloud offers benefits to sponsors with its data integrity, high accuracy, and verified reliability, solidifying its position as a new growth engine leading the future of clinical research.